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ABSTRACT
Obesity has become increasingly prevalent in the United States. Bariatric surgeries have
increased as the prevalence of obesity has risen, providing an effective alternative to weight loss.
Intravenous acetaminophen (IVA) is a safe and effective non-opioid medication that can be
given without the risk of respiratory or cardiac complications. Research has shown that the use of
IVA during surgery can improve postoperative pain scores, reduce opioid requirements, and
improve patient satisfaction.
A retrospective cohort study of 200 patients (100 per group) undergoing laparoscopic
bariatric surgery (LBS) was performed. Statistical analysis was used to determine the
relationship between those who received IVA near anesthesia induction or near end of surgery
and intraoperative/postoperative opioid consumption and pain scores. Other study variables
included: age, gender, American Society of Anesthesiologists (ASA) classification, Body Mass
Index (BMI), and length of anesthesia (LOA).
The results of the study determined there was no significant relationship between the
administration time of IVA and intraoperative/postoperative opioid consumption or pain scores.
There were significant relationships found between IVA administration time and BMI, age, and
LOA.
While no significant relationships were found related to the administration timing of IVA
and opioid consumption and pain scores, many studies have found efficacy in the use of IVA in
reducing opioid consumption and pain scores in a variety or procedures and populations.
Although this study did not provide results influencing the administration timing of IVA, it is
recommended that other studies follow a similar study design in further investigation into the use
of IVA to enhance anesthesia care and improve patient safety.
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OBJECTIVES
The primary objective of this study was to determine whether intravenous acetaminophen
(IVA) should be given near anesthesia induction or near the end of surgery to optimize
postoperative pain scores and minimize opioid consumption in patients undergoing laparoscopic
bariatric surgery (LBS). The hypotheses for this study are:
1. Patients who underwent LBS and received IVA within 30 minutes of anesthesia induction
will have lower intraoperative opioid consumption compared to patients who received
IVA within 30 minutes of end of surgery.
2. Patients who underwent LBS and received IVA within 30 minutes of anesthesia induction
will have lower postoperative opioid consumption compared to patients who received
IVA within 30 minutes of end of surgery.
3. Patients who underwent LBS and received IVA within 30 minutes of anesthesia induction
will have lower postoperative pain scores compared to patients who received IVA within
30 minutes of end of surgery.
BACKGROUND
The Center for Disease Control (CDC) defines obesity as a body mass index (BMI) of
greater than 30 in adults (CDC, 2016). Obesity is a growing concern for healthcare providers all
over the world. One study reported that the prevalence of obesity in the United States was
approximately 35% among men and women (Flegal, K. M., Carroll, M. D., Kit, B. K., & Ogden,
C. L., 2012). Obesity brings with it many comorbidities and risk factors for acute and chronic
illness that can complicate the patient’s response to anesthesia.
Among the comorbidities seen in obese patients, physiologic changes of the neck and
airway pose an increased threat to the safety of the patient during anesthesia care. Increased
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adipose tissue, particularly around the neck and oropharynx, can result in airway changes that
limit the patient’s ability to breathe and limit the anesthesia provider’s access to the airway.
Frequency of asthma and obstructive sleep apnea (OSA) in the obese patient are of serious
concern due to the difficulty in manual and/or mechanical ventilation when the patient is lying
flat and/or anesthetized (Thompson et al., 2011).
The prevalence of OSA in the obese population has been shown to be directly related to
BMI. A study of 290 patients preparing for weight loss surgery revealed that more than 70% of
patients with a BMI from 31-94 had OSA (Lopez, P. P., M.D., Stefan, B., M.S., Schulman, C. I.,
M.D., & Byers, P. M., M.D., 2008). A meta-analysis studying the postoperative outcomes of
patients with OSA showed that patients were more likely to experience oxygen desaturation,
respiratory failure, and require intensive care during the postoperative recovery period (Kaw, R.
et al., 2012). Due to the overwhelming difficulty of managing obesity as an illness many patients
have found successful treatment with weight loss surgery/LBS. The American Society for
Metabolic and LBS (ASMBS) reported that from the years 2011-2015 nearly 900,000 bariatric
procedures were performed in the United States (ASMBS, 2016). A meta-analysis performed by
Ribaric, G., Buchwald, J., & McGlennon, T. reported that LBS proved to be more effective than
other weight loss strategies (Ribaric, G. et al., 2013).
In order to provide optimal patient outcome for those undergoing LBS adequate
anesthesia depth and pain management are essential. Anesthetic gases, opioids, and other
adjunctive medications allow the anesthesia provider the greatest ability to maintain patient
safety. However, due to the common side effects of these medications, patients remain at risk
for adverse effects. Opioids commonly result in a depressed respiratory drive and decreased
mental alertness. A 2008 study showed that patients taking opioids were 67% more likely to
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experience OSA (Farney, R. J., Walker, J. M., Boyle, K. M., Cloward, T. V., & Shilling, K. C.,
2008). During anesthesia induction, these complications can be managed effectively by
performing laryngoscopy and tracheal intubation followed by mechanical ventilation. The
anesthesia provider can maintain airway protection during the intraoperative period in the same
manner and manage pain by administering opioids and other analgesics.
Airway protection has become the greatest concern for the care of obese patients during
the emergence of anesthesia (Greenwood, 2017). As patients emerge from anesthesia they
become aware of their surgical pain and pain management becomes of particular concern. Pain
management in the immediate postoperative period requires a balance of the patient’s alertness
and ability to breath spontaneously to maintain adequate ventilation. An imbalance of the
patient’s respiratory ability and analgesic administration in these crucial minutes after surgery
can result in respiratory distress/failure, cardiac depression, and even death. These serious
adverse effects can be due to an over-sedation effect (respiratory failure/cardiac depression) that
result in airway obstruction or a hyper-stimulatory effect that comes as a result of inadequate
pain control. A systematic review of more than 8,000 patients revealed that, in all included
studies, opioid administration resulted in an increase incidence of upper airway obstruction. This
review further showed that in many cases opioid administration correlated with decreased
respiratory compliance and airway reflexes (Ehsan, Z., Mahmoud, M., Shott, S. R., Amin, R. S.,
& Ishman, S. L., 2016).
Obese patients commonly suffer from OSA and are difficult to maintain pain control. A
study presented by the Journal of the American Society of Anesthesiologists reported that
patients with OSA experienced increased pain as compared to patients without OSA (Doufas, A.
G., Tian, L., Davies, M. F., & Warby, S. C., 2013). As obese patients have a significantly higher
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prevalence of OSA we can conclude that obese patients will likely experience increased pain
after surgery resulting in higher analgesic requirements. The administration of opioids during
the immediate postoperative period is of concern because it is the time when patients are the
most vulnerable to respiratory depression. An effective opioid dose to treat pain may
correspondingly be the dose that causes a depressed respiratory drive or decreased mental
awareness leading to inadequate ventilation and hypoxemia.
The increased risk that comes from opioid administration in the immediate postoperative
period leads the anesthesia provider to rely on multimodal therapies that enhance pain control
and limit dangerous adverse effects. IVA is a non-opioid analgesic that can be used to enhance
pain management in the surgical patient. While the exact mechanism of action of IVA is
unknown numerous studies have shown the efficacy of this medication as an analgesic. Singla et
al., showed that IVA had a significantly shorter time to maximum concentration compared to
oral or rectal acetaminophen resulting in a faster onset (Singla, NK., et al, 2012). The rapid onset
of IVA is due to its 100% bioavailability. The onset of action of IVA is approximately 15
minutes after the start of infusion at a dose of 15mg/kg with a maximum single dose of 1 gram
(age 13 years and greater) (Cadence Pharmaceuticals, a Mallinckrodt company, 2013). While
IVA is contraindicated in patients with a hypersensitivity to acetaminophen and those with
severe liver impairment, there are no reported adverse effects related to respiratory or cardiac
systems. IVA, used in multimodal therapy, has the ability to effectively enhance pain control
without increasing the risk of respiratory or cardiac depression. Unlike oral or rectal
acetaminophen, IVA does not undergo a first-pass hepatic effect which provides an increased
bioavailability leading to more effective pain control (Cadence Pharmaceuticals, a Mallinckrodt
company, 2013).
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The administration of IVA has been shown in numerous studies to be effective in
improving postoperative pain scores. A study by Atashkhoyi, S., Rasouli, S., Fardiazar, Z.,
Ghojazadeh, M., & Hatami, M. P. (2014), showed that 100 patients undergoing cesarean section
who received IVA 20 minutes before the end of surgery had significantly lower pain scores in
the post anesthesia care unit (PACU) (Atashhoyi et al., 2014). A study of 60 patients showed
significantly lower pain scores in cesarean section patients who received IVA 20 minutes
preoperatively (Ayatollahi, V., Faghihi, S., Behdad, S., Heiranizadeh, N., & Baghianimoghadam,
B, 2014). Another study found that in pediatric patients undergoing inguinal hernia repair
likewise showed significantly less pain scores in those who received IVA compared to the
placebo group (Kahlili et al., 2016). A 2014 study of patient satisfaction after surgery showed
that those receiving IVA reported a score of “excellent” (Apfel, C. C., Souza, K., Portillo, J.,
Dalal, P., & Bergese, S. D., 2014).
In addition to improved pain scores and patient satisfaction, IVA has been shown to
decrease opioid consumption in the intraoperative and postoperative periods. A retrospective
study by Song, K., Melroy, M. J., & Whipple, O. C. (2014), showed that 104 patients undergoing
LBS who received IVA intraoperatively required less morphine equivalents than the control
group who received opioid therapy only. This is one of the limited studies of IVA given to
patients undergoing LBS, and while it provides insight into the control of opioids related to this
patient population it did not find a significant reduction in pain scores in this population (Song et
al., 2014). This evidence supports the proposed study in that administration of IVA near
induction or EOS may be a factor in lowering pain scores in the postoperative period. A 2009
study of 90 women undergoing abdominal hysterectomy showed that those who got IVA 30
minutes before induction had lower postoperative pain scores and lower opioid requirements

INTRAOPERATIVE ADMINISTRATION OF IV ACETAMINOPHEN

10

than those who received IVA 30 minutes before EOS (Arici, S., Gurbet, A., Türker, G.,
Yavaşcaoğlu, B., & Sahin, S., 2009). This is one of the limited studies providing information
related to the difference in administration of IVA near induction or EOS. The study by Arici, et
al. in contrast to the study by Song, et al. supports the need for further investigation into the use
of IVA in patients undergoing LBS as it relates to administration timing. Jelacic et al. (2016),
showed that patients who underwent cardiac surgery used significantly less opioids compared to
the placebo group in the first 24 hours postoperatively after receiving IVA intraoperatively but
did not show a significant difference in pain scores between the two groups. (Jelacic et al., 2016).
A 2015 study of 92 patients who underwent LBS showed a nearly 40% decreased in opioid
requirements after having received IVA intraoperatively (Gonzalez, A. M., Romero, R. J., OjedaVaz, M. M., & Rabaza, J. R., 2015).
These studies provide a good foundation of efficacy for the use of IVA in surgical
patients. However, the limited information related to the use of IVA in reducing opioid
consumption and pain scores in patients undergoing LBS supports the need for further
investigation into this important patient population.
METHODOLGY
Design
The design for this study is a cross-sectional cohort. The cross-sectional study design
allows for the easy retrieval of patient data and case characteristics that were used to study the
relationships related to the use of IVA in patients undergoing laparoscopic bariatric procedures.
Sample
CAMC is a tertiary referral center located in Charleston, West Virginia. There are three
main hospitals in the Charleston area: General, Memorial, and Women and Children’s Hospitals.
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The CAMC health system performs more than 45,000 operating room procedures each year.
The CAMC General Hospital performs bariatric surgical procedures, has a dedicated bariatric
unit, and an associated Weight Loss Center (CAMC, 2017) (CAMCa, 2017) (CAMCb, 2017).
A chart review was performed on patients who underwent laparoscopic bariatric surgical
procedures at the General Hospital between January 1, 2007 and April 1, 2017. Two study
groups were compared as they relate to total intraoperative opioid consumption, total opioid
consumption during the first two hours of anesthesia recovery, pain scores recorded within 5
minutes of arrival in the post anesthesia care unit (PACU), and pain scores recorded at 1 hour
after arrival in the PACU.
The International Classification of Diseases, 9th and 10th revisions, Clinical Modification
ICD-9-CM and [ICD-10-CM] codes 44.38 [0D16479, 0D1647A, 0D164J9, 0D164JA, 0D164K9,
0D164KA, 0D164Z9, 0D164ZA] (Roux-en-Y gastric bypass, proximal/distal), 43.89
[ODB63ZZ], (unlisted laparoscopy, stomach), 44.95 [0DV64CZ] (Implantation of adjustable
gastric band) 44.82 [0DB64Z3] (Laparoscopy, sleeve gastrectomy) 44.96 [0DW64CZ]
(Replacement and revision of gastric band and port) were used for identification of patient
records that were included in the study.
•

Inclusion criteria consisted of patient’s age 18-65 years, American Society of
Anesthesiologists (ASA) classification of II-III, who underwent LBS lasting
between 60 and 180 minutes, and received IVA within 30 minutes of induction or
within 30 minutes of EOS.

•

Exclusion criteria consisted of patients outside ages 18-65; outside ASA
classification II-III; allergy to acetaminophen; history of: liver disease, opioid
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abuse, chronic pain, current use of opioids for acute/chronic pain; patients who
underwent open LBS; patients who underwent LBS and did not receive IVA or
did not receive IVA within 30 minutes of induction or end of surgery (EOS).

Procedures/Protocol
A retrospective study was performed using patient information gathered from the CAMC
EMR system for patients who underwent LBS. A sample of 200 patients who underwent
laparoscopic bariatric surgical procedures and received IVA were selected for this study and
assigned to one of two groups for comparison. The first group included 100 patients who
underwent LBS and received IVA within 30 minutes of anesthesia induction. The second group
included 100 patients who underwent LBS and received IVA within 30 minutes of EOS.
Age was assessed based on years of life upon hospital admission on the day surgery.
Gender was based on the gender recorded and/or reported by patient as indicated on the patient
record. ASA classification was assigned based on the pre-anesthesia assessment performed by an
anesthesiologist. BMI was calculated based on patient height and weight as recorded in the preanesthesia assessment and was used to assess for obesity. Length of anesthesia (LOA) is defined
as the time between anesthesia start time and anesthesia end time. Pain scores were based on the
assessment of PACU nurses and total postoperative opioid consumption will be based on the
total opioids given in the first 90 minutes in the PACU. Opioid consumption refers to the total
opioid amount measured in milligrams (mg) or micrograms (mcg) administered to the patient
and will include any opioids given during the preoperative, intraoperative, or postoperative
periods. All opioids were converted to morphine equivalents for calculation and comparison
between groups.
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Data Analysis
Data collected from the CAMC EMR system was analyzed as it relates to the primary
objective of the research study. The dependent variables include: total opioid consumption
during the intraoperative, total opioid consumption during the postoperative period, and pain
scores within 5 minutes of admission to PACU and at 1 hour after arrival in the PACU. The
primary independent variable was whether IVA was administered within 30 minutes of
anesthesia induction or 30 minutes of EOS. Secondary independent variables include: age,
gender, ASA classification, BMI, and LOA.
An independent t-test was used to compare the two groups based on age, BMI, and LOA.
A chi-square test was used to compare the two groups based on gender and ASA classification.
A step-wise regression statistical analysis was used to determine the relationship between IVA
administered within 30 minutes of anesthesia induction, IVA administered within 30 minutes of
EOS, age, gender, BMI, ASA classification and LOA; and the total intraoperative opioid
consumption, total postoperative opioid consumption, and pain scores on arrival in PACU and at
1 hour after arrival into PACU. A p-value of <.05 will determine statistical significance. The
data was analyzed using statistic analyzing software (SPSS).
RESULTS
During January 2007 and April 2017, a group of 200 patients that met inclusion criteria
were assigned to one of two groups based on the administration time of IVA in the intraoperative
period. Group 1 consisted of 100 patients who received IVA within 30 minutes of anesthesia
induction. Group 2 consisted of 100 patients who received IVA within 30 minutes of EOS.
Statistical analysis was performed to compare these two groups based on age, BMI, LOA,
gender, and ASA classification. An independent t-test was performed to compare the study
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groups based on age, BMI and LOS, and were found to have no significant differences. The two
groups were similar related to age, BMI, and LOA with values of 0.499, 0.692, and 0.266,
respectively (p>0.05) See Table 1. A chi-square test was used to compare the two groups based
on gender and ASA classification and was found to have no significant differences. The two
groups were similar related gender and ASA classification with values of 0.849 and 0.617,
respectively (p>0.5) [See Tables 2-3].
Table 1
IVGroup
Age (years)

LOA (min)

BMI

N

Mean

Std. Deviation

Std. Error Mean

Induction

100

42.610

10.2414

1.0241

End

100

43.640

11.2443

1.1244

Induction

100

107.220

16.6027

1.6603

End

100

104.510

17.7118

1.7712

Induction

100

47.2365

8.12251

.81225

End

100

46.7628

8.74444

.87444

Table 2
Gender (M/F)
F
IVGroup

End

Count

16

100

83.5

16.5

100.0

Std. Residual

.1

-.1

Count

83

17

100

83.5

16.5

100.0

-.1

.1

167

33

200

167.0

33.0

200.0

Expected Count
Std. Residual
Total

Total

84

Expected Count

Induction

M

Count
Expected Count
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Table 3
ASA2
0
IVGroup

End

Count

25

100

76.5

23.5

100.0

Std. Residual

-.2

.3

Count

78

22

100

76.5

23.5

100.0

.2

-.3

153

47

200

153.0

47.0

200.0

Expected Count
Std. Residual
Total

Total

75

Expected Count

Induction

1

Count
Expected Count

Several step-wise regressions were performed to compare the two groups related to
intraoperative/postoperative opioid consumption, and pain scores measured at within five
minutes of arrival to PACU and after 1 hour of admission to PACU. This statistical analysis
found no significant differences between the two groups as they relate to these variables. This
analysis did however find some significant relationships among other values.
The first step-wise regression was to show the relationship between when the IVA was
administered and the intraoperative opioid consumption. The other independent variables, age,
BMI, LOA, ASA classification, and gender, were also included. The results of this analysis are
given in Table 4. There was no relationship between when the IVA was given and the amount of
intraoperative opioid consumption. This analysis did however reveal that patients with increased
age received significantly less intraoperative opioids compared to others in the group with a
value of -0.389 (p<0.5). Furthermore, patients with an increased LOA received significantly
higher intraoperative opioids with a value of 0.127 (p<0.5) [See Table 4].
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Table 4
Standardized
Unstandardized Coefficients
Model
1

B
(Constant)
Age (years)

2

(Constant)
Age (years)
LOA (min)

Std. Error
47.300

3.173

-.378

.071

34.307

5.461

-.389

.070

.127

.044

Coefficients
Beta

t

Sig.

14.909

.000

-5.300

.000

6.282

.000

-.363

-5.544

.000

.189

2.897

.004

-.352

a. Dependent Variable: Opioid Total (intraop)

The second step-wise regression was to show the relationship between when the IVA
was administered and the postoperative opioid consumption with other independent variables
including: age, BMI, LOA, ASA classification, and gender. The results of this analysis are given
in Table 5. There was no relationship between when the IVA was given and the total
postoperative opioid consumption. This analysis did reveal that patients with an increased age
had significantly less opioid consumption compared to others in the group with a value of -0.121
(p<0.5) [See Table 5].
Table 5
Standardized
Unstandardized Coefficients
Model
1

B
(Constant)
Age (years)

a.

Std. Error
14.330

2.495

-.121

.056

Coefficients
Beta

t

-.151

Sig.

5.744

.000

-2.150

.033

Dependent Variable: Opioid Total (postop)

The third step-wise regression was to show the relationship between the IVA
administration time and the pain score upon admission to PACU. Other independent variables
included age, BMI, LOA, ASA classification, and gender. There was no relationship found
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between when the IVA was administered and the pain scores upon admission to PACU or any of
the independent variables.
The fourth, and last, step-wise regression performed was to show the relationship
between when the IVA was given and the pain scores recorded 1 hour after admission to PACU.
Other independent variables included age, BMI, LOA, ASA classification, and gender. The
results of this analysis are given in Table 6. No relationship was found between when the IVA
was given and the pain scores 1 hour after admission to PACU. There were however some
significant relationships related to BMI and LOA. As BMI increased, the pain score recorded 1
hour after admission to PACU was significantly decreased with a value of -0.180 (p<0.5). In
contrast, as LOA increased, the pain scores 1 hour after admission to PACU were also increased
with a value of 0.067 (p<0.5) [See Table 6].
Table 6
Standardized
Unstandardized Coefficients
Model
1

2

B
(Constant)

Std. Error
11.805

2.885

BMI

-.156

.060

(Constant)

5.828

3.888

BMI

-.180

.061

.067

.030

LOA (min)

Coefficients
Beta

t

Sig.

4.092

.000

-2.574

.011

1.499

.135

-.209

-2.967

.003

.159

2.264

.025

-.180

a. Dependent Variable: Pain Score (1hr)

DISCUSSION
The purpose of this research study was to determine if administration timing of IVA in
patients undergoing LBS had a significant relationship to the reduction of postoperative pain
scores or a decrease in total opioid consumption. The hypotheses of the study projected a
significant decrease in both pain scores and intraoperative/postoperative opioid consumption.
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The results of this study did not support any of the hypotheses as given. They did however, shed
light on some important correlations as related to patient demographics and procedure
characteristics such as age, BMI, and LOA. While anesthesia providers may have no control
over these variables the information gathered in this study can assist providers with more
efficient knowledge and an improved practice plan as it relates to this important patient
population.
The literature available related to the direct question of IVA administration timing is
limited. In direct comparison, our study and the study performed by Arici et al. did not have
correlating results. Arici et al. showed that patients who received IVA within 30 minutes of
induction of anesthesia had significantly less postoperative pain and used significantly less
opioids. These results did correlate with the hypothesis of this study. However, the comparative
was limited to patients undergoing abdominal hysterectomy and naturally one that is gender
specific. While our study gathered data on weight loss surgery, in general, there are multiple
variations of these types of procedures that were included in the data collection. This could be
one of the reasons the two studies did not have had correlating results. Where the comparative
only included females in their study, this study similarly, studied mostly females (167 compared
to 33 males). Overall, while our study compared to the study by Arici, et al. were constructed
similarly the two studies differed mainly in the type of procedures performed (Arici et al., 2009).
While this study collected patient data based on a variety of LBS procedures it is
expected that the variety of procedures did not have a significant impact on the results of the
study. Song, et al., reported that in a study comprised of over 100 patients undergoing various
bariatric procedures the IVA groups had no significant difference in pain scores compared with
the non-IVA groups included in the study (Song et al., 2014).

INTRAOPERATIVE ADMINISTRATION OF IV ACETAMINOPHEN

19

This study found that the most significant characteristics related to postoperative pain and
opioid consumption in patients undergoing LBS was age, BMI, and LOA. These results are
consistent with common practice methods related to opioid dosing and administration. As opioid
dosing is generally weight based in kilograms and administration is related to timing it is
expected that patients with an increased BMI will have an increased opioid requirement
compared to those with a lower BMI. Similarly, since opioids are metabolized at a specific rate,
dependent on the medication and the individual, it is expected that as the LOA is increased the
total opioid consumption will also increase. This is based on the assumption that the provider
desires to maintain the same amount of pain control during the entire procedure.
There are some increased risks to patient safety related to these results. As discussed, the
incidence of OSA in patients undergoing LBS is approximately 70% (Lopez, P. P., M.D., Stefan,
B., M.S., Schulman, C. I., M.D., & Byers, P. M., M.D., 2008). There are important risks
associated with OSA that impact patient safety when opioids are administered. Kaw et al., 2012
revealed obese patients with OSA are more likely to require intensive care due to postoperative
complications (Kaw, R. et al., 2012). In conjunction with an increased BMI, this patient
population can expect a variable LOA which may increase these risks due to the increased opioid
requirements as shown in this study. With an understanding that this high-risk patient population
is shown to have increased opioid requirements; anesthesia providers should remain vigilant in
recognizing patterns and taking precautions/preparations particularly during emergence and the
postoperative period.
Due to the nature of this retrospective design a variety of limitations may have had an
impact on the results of the study. The practice of the anesthesia provider may be the factor with
the largest impact. While all of the data collected consisted of patients who had procedures at
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the CAMC General Hospital, there are a variety of anesthesia providers involved in the care of
these patients. In addition to an inconsistent anesthetic plan due to a variety of providers, a
generalized anesthetic plan related to the procedure and not the patient may have impacted the
results of the study.
Other limitations as related to the patient population may have had an impact on the study
results. The primary variable influencing this study was the presence of pain. This variable
influenced all analgesics (opioid and non-opioid) administered intraoperatively and
postoperatively. In the same regard, the only analgesics included in the study were opioid based
analgesics and therefore may have impacted each of the primary results when the patient
received a non-opioid analgesic either intraoperative or postoperatively.
While comprehensive inclusion/exclusion criteria were used to select optimal groups for
this study design, it is possible that the histories as reported by the patient or collected by the
provider were inconsistent or incomplete. Furthermore, relating to the assessment of pain scores,
each provider may have inconsistent assessment methods compared to another provider. In the
same manner, each patient may interpret their pain differently than another patient in the same
situation. Each of these factors may have influenced both the pain scores and total opioid
consumption in the postoperative periods.
While some limitations exist, there are some important factors that strengthen this study
as a whole. The study design was appropriate for the purpose of the objectives. Furthermore,
this study design is applicable to any institution that provides similar services and can therefore
apply the information as appropriate. Each patient in either group met comprehensive
inclusion/exclusion criteria. These aspects yielded two study groups that were not significantly
different. The data collected was from procedures performed at the same facility and while there
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are many procedures performed here each year, the surgeons operating in this facility is limited.
The majority of the data collected of the 200 patient records had only two surgeons who
performed the operation. These factors provide consistency in the procedures performed and
limits the variability that could influence the study results.
RECOMMENDATIONS
This study was designed to contribute to the current literature by providing additional
insight as to the administration time of IVA in patients undergoing LBS. The results of this
study showed that there was no significant relationship between the two groups as they relate to
intraoperative/postoperative opioid consumption and postoperative pain scores. While no
significant relationship was found in this study, other studies conducted in a similar fashion
involving the use of IVA may yield additional information. It is recommended that the
application of this study design, particularly related to the administration timing of IVA, be used
in a variety of patient populations and a variety of procedures to further understand the use of
IVA and its ability as a non-opioid analgesic. Additionally, any study involving patients with an
increased BMI and the use of IVA may yield constructive information to assist in maintaining
patient safety in this high-risk population.
CONCLUSION
The primary objective of this study was to determine the relationship of the
administration timing of IVA and intraoperative/postoperative opioid consumption and
postoperative pain scores. It was hypothesized that the early administration of IVA would result
in an overall decrease in both opioid consumption and pain scores. However, the results of this
study showed that there was no significant relationship between these factors. While patients
with an increased BMI undergoing LBS are at an increased risk for complications, the
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administration timing of IVA may not have a direct impact on reducing these risks. Other studies
have shown efficacy in using IVA to reduce pain scores and opioid consumption. Therefore, IVA
should be regularly considered as an effective adjunct to opioid analgesia when creating an
anesthetic plan. The application of these principles will assist the anesthesia provider in
providing optimal care for each patient and increase overall patient safety.
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